Skip to content
AnalystLens

DEXCOM INC 8-K Report, Financial Results (Jul 25, 2024)

Reports
Earnings & Results·Other Events·Exhibits & Filings
Filing Date
Filed July 25, 2024
Period End
July 25, 2024
Security
DXCM
In the record · 2016–202610-K1110-Q328-K134

DXCM filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’17May ’17
  2. Material agreement8-K · May ’20May ’20
  3. Leadership change8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

01—Abstract

Summary

Summary of the 8-K filed July 25, 2024. Cited figures are marked; the original filing is the authoritative source.

DexCom reported second quarter 2024 results on July 25, 2024, with revenue of $1.004 billiona, up 15% year-over-year on a reported basis and 16% organic.

U.S. revenue grew 19% while international grew 7% reported (10% organic). GAAP operating income rose to $158.0 millionb (15.7% of revenue), and non-GAAP operating income reached $195.4 million (19.5% margin), up 130 basis points. GAAP diluted EPS was $0.35 and non-GAAP diluted EPS was $0.43.

Volume growth and new customer additions remained the primary growth driver, though management acknowledged that execution in the quarter 'did not meet our high standards.' Guidance was mixed. Management updated full-year 2024 revenue guidance to approximately $4.00c-4.05 billion (11-13% organic growth) and set Q3 2024 revenue guidance of roughly $975 million to $1.00 billion (1-3% organic growth), a sharp deceleration that management attributed to unique items affecting 2024 seasonality. Non-GAAP gross margin guidance was updated to about 63%, while non-GAAP operating margin (about 20%) and Adjusted EBITDA margin (about 29%) were reiterated.

Hardware revenue fell 39% year-over-year in the quarter, while sensor and other revenue grew 22%. The company also authorized a share repurchase program of up to $750 milliond, with a repurchase period ending no later than June 30, 2025. The program is discretionary and may be modified, suspended, or discontinued.

DexCom ended the quarter with $3.12 billion in cash and marketable securities, and its revolving credit facility remains undrawn. Investors should weigh the strong balance sheet and buyback against the sharp Q3 slowdown and the guidance-versus-execution concerns raised by management.

02—Key points

Key Highlights

  1. Q2 2024 revenue of $1.004 billion, up 15% YoY reported and 16% organic; U.S. revenue up 19%, international up 7% reported (10% organic)
  2. GAAP operating income of $158.0 million (15.7% margin), up 100 bps YoY; non-GAAP operating income of $195.4 million (19.5% margin), up 130 bps
  3. GAAP diluted EPS of $0.35 and non-GAAP diluted EPS of $0.43, versus $0.28 and $0.34 in Q2 2023
  4. Full-year 2024 revenue guidance updated to $4.00-4.05 billion (11-13% organic growth); non-GAAP gross margin guided to about 63%, with operating margin (~20%) and Adjusted EBITDA margin (~29%) reiterated
  5. Q3 2024 revenue guided to $975 million-$1.00 billion (1-3% organic growth), a significant slowdown that management attributes to unique seasonality items
  6. Board authorized a $750 million share repurchase program through June 30, 2025, at management's discretion with no obligation to repurchase
  7. Cash, equivalents and marketable securities of $3.12 billion at June 30, 2024; revolving credit facility undrawn

03—Questions

Frequently Asked Questions

  1. Why is DexCom guiding to such slow third-quarter revenue growth?

    The company guided Q3 2024 revenue to approximately $975 million to $1.00 billion, or 1-3% organic growth. Management attributed this to 'certain unique items impacting 2024 seasonality' but did not fully itemize them in the filing, so investors should seek clarification on the drivers during the earnings call and in subsequent filings.

  2. What does the $750 million share repurchase program mean for shareholders?

    The program authorizes buybacks of up to $750 million of common stock through June 30, 2025. Repurchases may occur in the open market, through privately negotiated deals, or under Rule 10b5-1 plans, but DexCom is not obligated to buy any amount and can modify or end the program at any time. Against $3.12 billion in cash and securities, the authorization is affordable, though the actual pace of execution will matter.

  3. Is DexCom's profitability improving?

    Yes, on both GAAP and non-GAAP bases. GAAP operating margin rose 100 bps to 15.7% and non-GAAP operating margin rose 130 bps to 19.5% year-over-year. Non-GAAP gross margin held at about 63.5% in the quarter, though GAAP gross margin slipped slightly to 62.4% from 62.7%.

  4. What does management mean by execution not meeting high standards?

    CEO Kevin Sayer said that while the company advanced strategic initiatives, 'our execution did not meet our high standards,' and that the company is 'taking action to improve our execution.' The filing does not specify the operational shortfalls, so the statement signals management concern but leaves the details open.

  5. What is driving the shift in revenue mix?

    Sensor and other revenue grew 22% to $947.0 million, now 94% of total revenue, while hardware revenue fell 39% to $57.3 million. Recurring sensor revenue is the primary growth engine, supported by volume growth and new customer additions, and the mix shift suggests a more recurring-revenue-oriented business model.

04—Continue

← View all 8-K filings